SciDev Ltd (AU:SDV)
ASX:SDV
Want to see AU:SDV full AI Analyst Report?
Top Page
SciDev Ltd
(Sydney:SDV)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.10
▼(-78.48% Downside)
Action:ReiteratedDate:05/02/26
The score is held back primarily by very weak technicals (price well below major moving averages with negative MACD and extremely low RSI), and by uneven fundamentals where 2025 showed a return to a small net loss and a sharp drop in free cash flow. A low-leverage balance sheet and improved gross margin provide some support, but not enough to offset the recent deterioration in profitability/cash conversion and bearish momentum.
Positive Factors
Low leverage / strong balance sheet
A conservatively levered balance sheet (debt-to-equity ~0.13) and a stable equity base provide durable financial flexibility. This supports bidding on long-term industrial contracts, funding working capital or capex without heavy refinancing, and better resilience through downturns.
Negative Factors
Volatile revenue growth
After rapid scaling from 2020 to 2025, a 5% revenue decline in 2025 highlights instability in demand or execution. Persistent top-line volatility impairs reliable forecasting, complicates capacity and investment planning, and raises the risk that scale advantages will not consistently materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A conservatively levered balance sheet (debt-to-equity ~0.13) and a stable equity base provide durable financial flexibility. This supports bidding on long-term industrial contracts, funding working capital or capex without heavy refinancing, and better resilience through downturns.
Read all positive factors
SciDev Ltd (SDV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.01M
Dividend YieldN/A
Average Volume (3M)156.16K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue Growth-6.98%
EPS Growth-243.52%
CountryAU
Employees22
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.01
Shares Outstanding190,088,580
10 Day Avg. Volume144,930
30 Day Avg. Volume156,164
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)1.26
Price to Sales (P/S)0.61
P/FCF Ratio80.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$94.72M
SciDev Ltd Business Overview & Revenue Model
Company Description
SciDev Limited engages in supply of process control, professional services, equipment design and construction, and chemistry in Australia and the United States. The company offers coagulants and flocculants in powder and liquid form under the Maxi...
How the Company Makes Money
SciDev Ltd generates revenue by manufacturing and supplying specialized chemical products, such as coagulants and flocculants, which are essential for water treatment and waste management in industries. The company earns money through its direct s...
SciDev Ltd Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
72
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 101.34M | 103.50M | 109.09M | 89.72M | 55.60M | 42.52M |
| Gross Profit | 18.57M | 33.39M | 33.97M | 6.83M | 3.69M | 1.37M |
| EBITDA | 3.28M | 5.91M | 7.65M | 4.11M | 1.13M | 1.88M |
| Net Income | -2.95M | -878.00K | 2.17M | -339.00K | -616.00K | 3.45M |
Balance Sheet | ||||||
| Total Assets | 71.24M | 75.23M | 72.01M | 67.37M | 71.16M | 56.15M |
| Cash, Cash Equivalents and Short-Term Investments | 7.52M | 9.68M | 9.43M | 7.73M | 14.06M | 7.01M |
| Total Debt | 6.61M | 6.26M | 5.13M | 3.48M | 2.90M | 5.13M |
| Total Liabilities | 23.81M | 25.18M | 21.78M | 19.35M | 22.32M | 24.54M |
| Stockholders Equity | 47.43M | 50.05M | 50.24M | 48.02M | 48.84M | 31.61M |
Cash Flow | ||||||
| Free Cash Flow | -2.13M | 785.00K | 4.48M | 522.00K | -3.83M | -1.92M |
| Operating Cash Flow | -1.00K | 2.87M | 6.48M | 4.81M | -1.31M | -1.32M |
| Investing Cash Flow | 366.00K | -2.35M | -3.71M | -8.39M | -6.65M | -2.49M |
| Financing Cash Flow | -3.31M | -390.00K | -1.06M | -2.83M | 14.99M | 6.34M |
SciDev Ltd Technical Analysis
Negative
0.46
Price Trends
0.25
Negative
0.35
Negative
0.34
Negative
Market Momentum
-0.02
Negative
24.28
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SDV, the sentiment is Negative. The current price of 0.46 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.25, and above the 200-day MA of 0.34, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 24.28 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SDV.
SciDev Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | AU$36.36M | -2.95 | -97.12% | ― | ― | 8.16% | |
55 Neutral | AU$32.93M | -2.92 | -82.31% | ― | 23.44% | 42.80% | |
48 Neutral | AU$19.01M | -10.44 | -6.05% | ― | -6.98% | -243.52% | |
44 Neutral | AU$21.89M | -1.13 | 242.65% | ― | -35.41% | -86.36% | |
43 Neutral | AU$121.92M | -1.24 | -73.16% | ― | 21.36% | -70.37% | |
42 Neutral | AU$24.95M | -0.58 | 483.00% | ― | ― | -42.68% |
* Basic Materials Sector Average
AU:SDV
SciDev Ltd
0.10
-0.28
-73.68%
AU:AJX
Alexium International Group
―
―
―
AU:DTZ
Dotz Nano Limited
0.04
-0.06
-61.70%
AU:SPN
Sparc Technologies Ltd
0.31
0.15
90.62%
AU:CXL
Calix Ltd.
0.57
0.16
41.25%
AU:CG1
Carbonxt Group Ltd.
0.08
0.03
65.22%
SciDev Ltd Corporate Events
SciDev Director Dan O’Toole Increases Indirect Shareholding via On-Market Purchase
May 4, 2026
SciDev Ltd has reported a change in the indirect shareholding of director Dan O’Toole, as disclosed to the ASX under directors’ interest reporting requirements. The filing notes that O’Toole holds his indirect interest through Hu...
AustralianSuper exits substantial holder position in SciDev Limited
Apr 30, 2026
SciDev Limited has disclosed that AustralianSuper Pty Ltd has ceased to be a substantial shareholder in the company as of 28 April 2026, following a series of share disposals executed through JPMorgan Nominees Australia. The transactions between 2...
SciDev Director Increases Indirect Shareholding via On-Market Purchase
Apr 30, 2026
SciDev Ltd has disclosed a change in director Johannes Risseeuw’s indirect shareholding, lodged under ASX listing rule 3.19A.2. The shares are held through the JC Risseeuw Superannuation Fund, indicating the interest is beneficial but indire...
SciDev director Jon Gourlay lifts on-market shareholding
Apr 30, 2026
SciDev Ltd has disclosed a change in director Jon Gourlay’s shareholding, with the board member increasing his direct stake in the company through a series of on-market trades executed between 24 and 29 April 2026. Gourlay acquired 241,626 f...
SciDev cuts FY26 revenue guidance but flags stronger FY27 outlook
Apr 19, 2026
SciDev reported its third consecutive quarter of positive underlying EBITDA in 3Q FY26, with margin improving to 6% and Process Chemistry on track for record full-year revenue, underpinned by fully implemented cost reductions that lower corporate ...
SciDev director Mike Utsler lifts stake with on‑market share purchase
Mar 9, 2026
SciDev Ltd has disclosed a change in the shareholding of director Mike Utsler, who increased his direct holding in the company through on-market purchases executed between 4 and 6 March 2026. The transactions involved acquiring 150,000 fully paid ...
SciDev director Dan O’Toole lifts indirect shareholding with on-market purchase
Feb 27, 2026
SciDev Ltd has disclosed a change in director Dan O’Toole’s relevant interest in the company’s securities, reflecting an increase in his indirect shareholding through Huon Road Pty Ltd . The disclosure, lodged with the ASX, detai...
SciDev Hit by Energy Disruptions and Cost Pressures in First Half FY26
Feb 25, 2026
SciDev Ltd reported a challenging first half of FY26, with revenue slipping to $47.9 million from $49.9 million a year earlier and gross margins contracting to 28%. Management attributed the weaker performance primarily to disruption in fracturing...
SciDev outlines turnaround plan after challenging first half
Feb 25, 2026
SciDev reported a weaker first half of FY26, with revenue slipping to A$47.9 million and underlying EBITDA falling to A$1.1 million, as a frac schedule change at a key U.S. energy customer hit xSlik® sales and international Water Technologies...
SciDev Swings to Deeper Half-Year Loss on Modest Revenue Decline
Feb 25, 2026
SciDev Limited reported half-year revenues of $47.9 million for the period ended 31 December 2025, down 4% from a year earlier, while its net loss after tax widened sharply to $2.14 million from $68,000. The result pushed basic and diluted earning...
SciDev sets date for 1H FY26 results and investor webcast
Feb 23, 2026
SciDev Ltd will release its first-half FY26 financial results before the market opens on 26 February 2026 and will host an investor webcast the same morning. The online briefing, led by Managing Director and CEO Seán Halpin and CFO Todd Scott...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.